Table 2 Univariate analysis of survival-related characteristics in platinum-sensitive recurrent ovarian cancer
From: Secondary cytoreduction surgery improves prognosis in platinum-sensitive recurrent ovarian cancer
Variable | TTP (OR 95% CI) | OS (OR 95% CI) |
|---|---|---|
FIGO stage | ||
I | 1.00(reference) | 1.00(reference) |
II | 1.25(0.57–4.31) | 1.44(0.66–4.45) |
III | 3.09(1.53–8.36) | 3.71(2.34–8.95) |
IV | 4.64(2.85–12.26) | 4.96(2.51–11.14) |
Grade | ||
Low | 1.00(reference) | 1.00(reference) |
High | 5.22(2.14–12.76) | 4.02(1.95–10.33) |
Ascites | ||
No | 1.00(reference) | 1.00(reference) |
Yes | 1.78(1.44–2.38) | 1.94(1.48–2.27) |
Optimal initial CRS | ||
Yes | 1.00(reference) | 1.00(reference) |
No | 6.07(2.50–15.91) | 6.84(3.32–13.86) |
Optimal secondary CRS | ||
Yes | 1.00(reference) | 1.00(reference) |
No | 5.28(1.86–16.93) | 9.30(4.29–19.51) |
Neo-chemotherapy | ||
Yes | 1.00(reference) | 1.00(reference) |
No | 1.19(1.04–1.57) | 1.45(0.79–2.75) |
Paclitaxel-based chemotherapy | ||
Yes | 1.00(reference) | 1.00(reference) |
No | 1.02(0.85–1.39) | 1.35(0.83–2.01) |
PFS | 1.02(1.00–1.18) | 1.13(1.07–1.30) |
Nadir CA-125 | 1.02(1.00–1.03) | 1.03(1.00–1.06) |